Review
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

M. De Hert a,*, J.M. Dekker b, D. Wood c, K.G. Kahl d, R.I.G. Holt e, H.-J. Möller f

a University Psychiatric, Centre Catholic University, Leuven campus Kortenberg, Leuvensesteenweg 517, 3070 Kortenberg, Belgium
b Department of Epidemiology and Biostatistics and the EMGO, Institute for Health and Care Research, VU University Medical Centre, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
c National Heart and Lung Institute Cardiovascular Science, Imperial College, Charing Cross Campus, W6 8RP London, United Kingdom
d Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neubergstrasse 1, 30625 Hannover, Germany
e Endocrinology & Metabolism, Developmental Origins of Health and Disease, School of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
f Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstrasse 7, 80336 Munich, Germany

Received 22 January 2009; accepted 29 January 2009
Available online 13 August 2009

Abstract

People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors: obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.

© 2009 Elsevier Masson SAS. All rights reserved.

Keywords: Severe mental illness; Schizophrenia; Depression; Bipolar disorder; Physical health; Weight gain

1. Introduction

People with severe mental illnesses (SMI), such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population [58,82,84,124]. Evidence shows that they have a 2–3 fold increased mortality rate and that the mortality gap associated with mental illness compared to the general population has widened in recent decades [113]. This excess mortality is not only caused by increased suicide; people with SMI have an increased risk of mortality associated with physical illness, with the commonest cause of death being cardiovascular disease (CVD) [15,16,17,25,26,65,82,103,104,106,107]. The aetiology of this excess CVD is multifactorial and includes genetic and lifestyle factors as well as disease specific and treatment effects. People with SMI are more likely to be overweight, to smoke and to have diabetes, hypertension and dyslipidaemia [31,39,45,46,93,99,100,121]. They are more
likely to have a family history of diabetes and the illness is associated with chronic elevations of stress hormones. Antipsychotic medication can induce weight gain or worsen other metabolic CVD risk factors [5,51,61,64,99,100,116,117,119,129,134,136]. There is emerging evidence that modifiable cardiovascular risk factors are also increased in patients with bipolar disorders and in those with a history of depression or taking drugs to treat depression [8,12,13,15,16,25,27,38,67,71,72,75,91,92,112,114,135]. The scientific literature regarding the effects of medications used in the treatments of unipolar or bipolar depression, such as antidepressants or mood stabilisers, is currently less comprehensive than for antipsychotics [11,12,15,91,92,141].

Despite the increased risk of diabetes and CVD risks, many patients with SMI have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population [49,58,82,84,87]. Low rates of treatment for hypertension, dyslipidaemia and diabetes have been reported in schizophrenia patients [96]. The lack of consensus over who should take responsibility for the general healthcare needs of patients with mental illness has resulted in a continuing failure to provide appropriate services.

Psychiatrists and primary care physicians should play an active role in ensuring that patients with mental illness are not disadvantaged. Measures should include the assessment and management of cardiovascular risk factors and diabetes as part of the care of their psychiatric patients. When indicated, shared care with cardiologists, diabetologists, specialist nurses or other specialists should be established.

The aim of the joint statement of European Psychiatric Association (EPA), European Association for the Study of Diabetes (EASD) and European Society of Cardiology (ESC) is to reduce cardiovascular risk and to improve diabetes care in patients with SMI and to improve the overall health and well-being of the patients. This should reduce the burden of physical illness for patients, their families and healthcare services.

Based on a review of the evidence that patients with SMI are at increased risk of CVD and diabetes, this position statement has been developed by the EPA, in consultation with the EASD and the ESC. The statement is based upon the guidelines of ESC and EASD [59].

2. Who is at risk and why?

2.1. Cardiovascular disease

Epidemiological studies have consistently shown excess CVD mortality in patients with schizophrenia, bipolar disorder and depression [8,15,17,18,24,26,35,82,83,106,107,113,124]. In a recent meta-analysis of 37 studies carried out in 25 countries, with an estimated total of nearly 23,000 deaths, people with schizophrenia had a median all-cause standardised mortality rate (SMR) of 2.58 (90% quantiles 1.18–5.76) (2.41 for all natural causes [90% quantiles 0.99–4.10], 7.5 for all unnatural causes [90% quantiles 5.56–12.73]) [113]. The median SMR for CVD was 1.79 (90% quantiles 1.11–3.60).

The median all-cause SMR for people with schizophrenia during the 1970s, 1980s and 1990s were 1.84, 2.98 and 3.20, respectively, demonstrating increasing health inequalities with an increasing mortality gap over time.

Similar findings have been reported in large studies of people with affective disorders with an overall SMR ranging from 1.23 to 2.50 [8]. In a subset of 400 patients with unipolar depression or bipolar disorder followed up for 34–38 years, the SMR for coronary heart disease (CHD) was 1.61 (confidence interval [CI] 1.31–3.54). Compared with healthy women, women with depression were particularly at risk of CHD mortality (SMR 1.7, CI 1.34–2.14), while men showed increased cerebrovascular and vascular mortality (SMR 2.21, CI 1.29–3.54). The Baltimore Maryland Epidemiological Catchment Area Study, which was a 13 years follow-up study of a representative US community sample assessed for common psychiatric illness, reported a 4.5 fold increased odds ratios for myocardial infarction in patients with depression [57,109].

The aetiology of this excess CVD is multifactorial and includes genetic and lifestyle factors as well as disease specific and treatment effects. The excess CVD mortality associated with schizophrenia, unipolar and bipolar disorder is widely attributed to the 1–5 fold relative risk of the modifiable CVD risk factors, obesity, smoking, diabetes, hypertension and dyslipidaemia, in this group of patients compared with the general public (Table 1) [5,9,13–16,39,41,43,47,64,65,74,88,94,99,100,116,117,119,121,129,133,135,136].

In the USA, 68% of 689 schizophrenia patients who took part in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study were smokers compared to 35% of age matched controls, 13% had diabetes versus 3% of controls and 27% versus 17% had hypertension [60]. Patients with schizophrenia also had significantly lower HDL-cholesterol (HDL-C) levels. Approximately one third of patients in CATIE had a constellation of metabolic and cardiovascular risk factors at baseline [93].

In a meta-analysis including 12 papers on hypertension and 11 on dyslipidaemia, there was a pooled risk ratio of 1.11 (0.91 to 1.35) of hypertension. Although total cholesterol was not higher in people with SMI (standardized mean difference –0.10 [–0.55 to 0.36]), some, but not all, studies reported lower levels of HDL-C and raised triglyceride levels [104].

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Estimated prevalence and relative risk of modifiable cardiovascular disease risk factors in schizophrenia and bipolar disorder compared to the general population [39,47].</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modifiable risk factors</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Obesity</td>
<td>45–55% RR: 1.5–2</td>
</tr>
<tr>
<td>Smoking</td>
<td>50–80% RR: 2–3</td>
</tr>
<tr>
<td>Diabetes</td>
<td>10–15% RR: 2</td>
</tr>
<tr>
<td>Hypertension</td>
<td>19–58% RR: 2–3</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>25–69% RR: ≤ 5</td>
</tr>
<tr>
<td>Metabolic Syndrome</td>
<td>37–83% RR: 2–3</td>
</tr>
</tbody>
</table>

RR: relative risk.
An increased risk of overweight, obesity and diabetes mellitus type 2 has also been found in clinical populations with affective disorders [12,15,27,38,67,75,88,91,94].

Despite the high prevalence of cardiovascular risk factors, there is evidence of undertreatment of these modifiable risk factors. In the CATIE study, 88% of patients with dyslipidaemia were receiving no treatment while 62% of those with hypertension and 38% of those with diabetes also received no treatment [96]. The high prevalence of undertreatment of cardiovascular risk factors was recently confirmed in a study of 2463 people with schizophrenia from 12 European countries [45]. Overall, 10.9% of patients were being treated for hypertension, 7.1% for a lipid disorder and 3.5% for type 2 diabetes. Biochemical evidence of hyperglycaemia and dyslipidaemia, however, was found in 26 and 70% of patients respectively and untreated hypertension was found in 39%.

An unhealthy lifestyle, including poor diet and sedentary behaviour, is likely to contribute to the adverse risk profile of people with SMI. Given the weight gain and other metabolic abnormalities associated with some second-generation antipsychotic agents (SGA), however it has been difficult to differentiate the contribution of psychiatric conditions and treatment per se to increased CVD risk [5,99,100,116,117,119,130].

A large, ongoing, prospective study has confirmed that many patients with first episode schizophrenia already have significant metabolic abnormalities at the time of their first episode of illness [43]. Twenty-seven percent of patients had raised total cholesterol at first episode, rising to 61% in patients with a long duration of illness. In addition, patients with first episode psychosis have been found to have altered body composition with increased intra-abdominal fat deposition as opposed to subcutaneous fat, which itself has emerged as a strong and independent risk factor for the development of CVD [77,108,126,127]. The latter findings underline the importance of possible metabolic alteration before the influence of psychopharmacological treatment and support the hypothesis that metabolic abnormalities are an inherent part of schizophrenia, with socioeconomic factors and possibly that metabolic abnormalities are an inherent part of schizophrenia and bipolar illness [13].

The association between depression and diabetes is complex and there is evidence that the association is bidirectional [16,67,112]. People with established diabetes have higher rates of depression than the general population, while depression has become established as a risk factor for diabetes. There are several mechanisms to explain this association from the “psychological stress” resulting from the diagnosis and treatment of the physical illness, through the metabolic derangement leading to mood disturbance to alterations in cytokines and stress hormones.

3. Psychopharmacological treatment and cardiovascular disease risk

Psychopharmacological treatment with antipsychotics, antidepressants and mood stabilisers is an effective and necessary component of the management of severe mental disorders like schizophrenic and affective disorders. As it is well established that people with SMI who do not take
medication have a higher risk of mortality, suicide and hospital admission than those who are on regular medication [128]; any adverse metabolic effect needs to be placed within the context. Although the relationship between antidepressants and mood stabilisers and weight gain is well described, the scientific literature on the association between antipsychotics or mood stabilisers and cardiovascular risk is sparse. There is, however, a considerable literature about the adverse effects of antipsychotics.

Growing evidence suggests that children and adolescents who take antipsychotic medication are at higher risk of weight gain and metabolic effects than adults who use the same drugs [32,36,79,80,103].

3.1. Weight gain

Weight gain during acute and maintenance treatment of schizophrenia and affective disorders is a well established side effect of antipsychotics affecting between 15–72% of patients [1,2,5,11,29,51,61,71,85,88,101,116,117,130]. Antidepressants and mood stabilising drugs, such as lithium and valproate, may also induce significant weight gain.

There is a marked difference in the risk of weight gain between different antipsychotic drugs. A meta-analysis of clinical trials showed that after 10 weeks of treatment, weight gain was greatest with clozapine (4.45 kg) and olanzapine (4.15 kg) while quetiapine and risperidone (2.1 kg) had an intermediate risk and aripiprazole, amisulpride and ziprasidone have little effect on weight (<1 kg). No agent, however, should be considered as truly weight-neutral as the proportion of individuals experiencing more than 7% weight gain is greater with any atypical antipsychotic than placebo [29]. It should be underlined that in the meta-analysis by Allison et al. [1], some of the first-generation antipsychotics (FGA or neuroleptics) like chlorpromazine also showed a comparably high risk of inducing weight gain. This hierarchy for risk of weight gain has been confirmed in the more recent CATIE, the European EUFEST studies and a meta-analysis [41,60,73,85,86].

There is marked inter-individual variation in weight change for each drug, which may range from dramatic weight gain to weight loss. Although weight gain is unpredictable for an individual, there are several demographic and clinical features that are associated with a greater propensity for weight gain and should aid clinical decision-making (Table 2). In particular, children and adolescents are at high risk of significant weight gain. Early weight gain (> 7% body weight within the first 6 weeks of olanzapine treatment) appears to be a good predictor of subsequent significant weight gain [76]. A comprehensive literature review, however, did not find evidence for a dose–response at the doses used to treated psychotic illnesses for most antipsychotics, except clozapine and olanzapine [118].

Among the antidepressants, tricyclic agents (most notably amitriptyline and doxepine), mirtazapine and paroxetine seem to be associated with a higher risk of weight gain [91,92,123].

The mechanisms leading to antipsychotic-induced weight gain are complex and are not fully understood. The main mechanism of weight gain appears to be through appetite stimulation but other less specific mechanisms, such as altered energy expenditure, may also be involved. Antipsychotics interact with many different brain receptors involved with appetite regulation, the most important of which are the histamine H1 receptor, 5-HT2c receptor and β3 and α1 adrenergic receptors [5,71,96,99,100,116,117,130].

3.2. Dyslipidaemia

Prospective studies show that the use of antipsychotics is associated with an increase in LDL cholesterol and decrease in HDL-C [41,60,69,70,93]. Furthermore some comparative studies have indicated that the effect on total and LDL cholesterol differs between antipsychotics. At present, it is uncertain whether these short-term changes will translate into clinically relevant differences in the long term [41,60,73,93,122,134,139].

The overall effect on triglycerides is more marked and here there are clear differences between drugs; those drugs associated with the most weight gain, such as clozapine and olanzapine, are associated with the largest rise in serum triglycerides [41,60,73,93,122,134,139]. The most marked differences between drugs are seen in the early phase of treatment when weight gain occurs most rapidly. In a recent study on different cardiovascular risk factors in patients diagnosed with schizophrenia from 2000–2006 compared to 1984–1995, those treated with SGA for 3 years gained twice as much weight and showed greater deterioration in triglyceride than those treated with FGA drugs for three years [46].

Most studies report lipid measurements after short periods of treatment (2–3 months) and there is a need to assess what the longer-term effects on triglyceride concentrations are once weight has stabilised.

3.3. Hypertension

The literature does not show a consistent association between SMI and hypertension. Antipsychotic drugs may worsen hypertension through weight gain but this may be offset by a hypotensive effect through adrenergic blockade.

3.4. Diabetes

An evaluation of the data regarding antipsychotic drugs is challenging because of the increased risk of diabetes among people with SMI. It is also complicated by the frequent changes
in psychotic medication made by people with SMI against the long natural history of diabetes. The sources of information range from case histories, through pharmaco-epidemiological studies to randomised controlled studies. Many of these studies have significant flaws and so it is not possible to draw firm conclusions about the risks of diabetes with antipsychotic medication [70].

Observational studies would suggest that there is an increased risk of diabetes in people receiving an antipsychotic medication. These studies, however, may be confounded by the increased risk of diabetes in people with SMI. A recent meta-analysis of the risk of diabetes in people with schizophrenia receiving antipsychotics showed that there was a 1.32 (95% CI 1.15–1.51) fold increased risk of diabetes in people taking SGA compared with conventional antipsychotics [119]. In this study, no difference was found in the risk of diabetes between different SGA. In a further systematic review of observational cohort studies, the attributable risk for individual SGA relative to FGA ranged from 53 more to 46 fewer new cases of diabetes per 1000 patients with little observable difference between the individual SGA versus FGA [30]. Furthermore, a systematic review of the 22 prospective randomised controlled trials found no consistent significant glucose abnormalities between any comparator antipsychotics or placebo in any trial [21].

Although these studies would suggest that the risk of diabetes associated with SGA medication is low, several caveats are needed. There are clearly some cases of diabetes and diabetic ketoacidosis that have occurred following treatment with antipsychotic medication, including somewhere this has occurred following re-challenge with the antipsychotic. Diabetes may also remit following the discontinuation of treatment.

Furthermore in several randomised controlled trials (RCT), differences in blood glucose have been observed. For example, in the CATIE study, there was a significantly greater increase in HbA1c with olanzapine (0.4%) compared with quetiapine (0.04%), risperidone (0.07%), perphenazine (0.09%) and ziprasidone (0.11%). If these changes persisted with longer treatment, they may translate into clinically meaningful differences in the rates of diabetes between drugs [86].

The mechanism by which antipsychotic drugs induce diabetes is not clear and again is likely to involve several different systems. As well as an indirect effect on the risk of diabetes through weight gain, in vitro and animal studies have demonstrated that antipsychotics may have an effect on insulin secretion and insulin resistance [99,105,116,117,130].

Overall, the evidence is clear that the use of antipsychotics is associated with an increased risk of diabetes but this risk is small compared with other traditional diabetic risk factors. The evidence for a differential effect between different antipsychotics is less conclusive. Given our understanding in the relationship between obesity and diabetes, it is likely that that where there is significant antipsychotic induced weight gain leading to obesity over a prolonged period of treatment, this may contribute to the development of diabetes. As such there may be differences between antipsychotics in their risk for diabetes.

3.5. Cardiovascular events

A large UK study involving 46,136 people with SMI and 300,426 healthy controls demonstrated that the hazard ratios (HR) for CHD mortality in people with SMI compared with controls were 3.22 (95% CI, 1.99–5.21) for people 18 through 49 years old, 1.86 (95% CI, 1.63–2.12) for those 50 through 75 years old and 1.05 (95% CI, 0.92–1.19) for those older than 75 years. For stroke deaths, the HR were 2.53 (95% CI, 0.99–6.47) for those younger than 50 years, 1.89 (95% CI, 1.50–2.38) for those 50 through 75 years old and 1.34 (95% CI, 1.17–1.54) for those older than 75 years. Compared with healthy controls, people with SMI who were not prescribed any antipsychotics were at increased risk of CHD and stroke than controls, whereas those prescribed such agents were at even greater risk. Those receiving the higher doses were at greatest risk of death from both CHD and stroke. Exposure to atypical antipsychotics, however, was not related to CHD mortality. Compared with the non-SMI control group, the fully adjusted HR for CHD death in the SMI subgroups were as follows: 1.38 (95% CI, 1.08–1.76) for those not prescribed any antipsychotics, 0.86 (95% CI, 0.52–1.41) for those ever prescribed atypical antipsychotics and 2.12 (95% CI, 1.82–2.47) for those receiving conventional antipsychotics only [104]

A well conducted retrospective pharmaco-epidemiological cohort study involving over 90,000 people receiving antipsychotics found a 1.99–2.26 fold increased rate of sudden cardiac death in current users of typical and atypical antipsychotics [110]. The risk increased with higher doses and was not seen in former users of antipsychotics. There was no difference between typical and atypical antipsychotics. The underlying reason for this finding was not fully established in this study.

At the present time, there are no outcome data for the differences in weight gain and risk of diabetes and dyslipidaemia with each of the SGA’s in terms of hard endpoints, such as non-fatal and fatal CVD and total mortality.

4. Guidelines for screening and monitoring of cardiovascular disease risk factors and diabetes

Over recent years, both national and international groups have developed screening and monitoring guidelines [5,10,22,31,34,42,48,90,115,133,137] but these are not being routinely implemented in the clinical care of patients [20,63,87,99], although they appear to be cost-effective [19]. The most recent NICE schizophrenia guidelines include the need for comprehensive physical health monitoring and involvement of general practitioners [102]. Some recent diabetes guidelines have defined a diagnosis of schizophrenia and antipsychotic use as risk factors for diabetes [4,23].

5. Assessment of cardiovascular disease risk

The European Guidelines on CVD prevention recommend that people with known CVD, type 2 diabetes or type 1 diabetes with microalbuminuria or with very high levels of individual
risk factors should automatically have all their risk factors actively managed [59].

For other people, the Guidelines recommend that risk factors should be managed according to the total CVD risk, as assessed by the Score risk charts which calculate risk according to age, sex, smoking habit, systolic blood pressure and total cholesterol, or the ratio of total to HDL-C [59]. These charts focus risk management on men over 50 and women over 55.

Recent evidence suggests that patients with SMI are typically younger, have higher blood pressure and are more likely to be smokers than the populations used to derive CVD risk scoring systems, such as Framingham and Score and there is a need to validate a risk score for this specific population of mentally ill patients [9,19,37,41,60,125].

To ensure that younger patients at high CVD risk compared to others the same age do not miss out on treatment, the European Guidelines on CVD prevention include a relative risk chart which bases the relative risk on smoking habit, systolic blood pressure and total cholesterol (Fig. 1).

In the current absence of a risk scoring system for people with SMI [125] and given the excess CVD mortality in people with SMI outlined earlier, we recommend that the decision to manage CVD risk factors in this group of patients should be based on relative risk, as shown in Fig. 1. Where individual risk factors are markedly raised, there may also be a need to manage these on an individual basis.

As obesity and metabolic abnormalities are also seen in children and adolescents who take antipsychotic medication are at particularly high risk [32,36,79,80,103], we recommend close monitoring of risk factors such as weight and lipid levels in this group, with appropriate dietary, lifestyle and therapeutic intervention, in line with recent paediatric guidance [40].

5.1. Which tests and when?

CVD risk assessment in the general population is usually carried out within a primary care setting. Many patients with serious mental health problems, however, frequently have poor access to general healthcare services. Such annual screening for CVD and metabolic disorders in patients with SMI, however, can be cost effective, owing to the reduction in costs of treating the complications of diabetes [19,59].

Psychiatrists are often best placed to coordinate CVD risk assessment and management, ideally as part of shared care arrangements with general and specialist healthcare services.

It is particularly important to establish baseline CVD risk at initial presentation so that any subsequent change during treatment can be monitored.

The medical history and examination should therefore include:

- history of previous CVD, diabetes or other related disease;
- family history of premature CVD, diabetes or other related disease;
- smoking habit;
- weight and height in order to calculate body mass index (BMI) and waist circumference;
- fasting blood glucose;
- fasting blood lipids: total cholesterol, triglycerides, LDL-cholesterol (by calculation) and HDL-C;
- blood pressure (measured twice and average taken), heart rate, heart and lung auscultation, foot pulses;
- ECG.

Normal and abnormal values for fasting blood glucose, fasting blood lipids and blood pressure are provided in Table 3.

It is recommended that measurements should be taken at the initial presentation and before the first prescription of antipsychotic medication (Fig. 2). The frequency of testing will depend on the patient’s medical history and the prevalence of baseline risk factors.

For patients with normal baseline tests, it is recommended that biochemical measurements are repeated at 6 weeks and 12 weeks after initiation of treatment and at least annually thereafter. The frequency of testing will depend on the presence of risk factors and detected abnormalities. During the initial phase of treatment, it is important to measure weight weekly to identify those individuals who gain weight rapidly with psychotropic treatment.

In patients with diabetes, an assessment of glycaemia control by HbA1c should be made regularly (approximately every 3 months) [6].

6. Management of cardiovascular disease risk factors

The recommended interventions for management of CVD risk factors are summarised in Fig. 2.

6.1. Smoking habit

Smokers should be encouraged to stop smoking all forms of tobacco. Those who demonstrate a readiness to quit can be referred to a smoking cessation service which can offer behavioural counselling, nicotine replacement therapy or other pharmacological intervention.
Table 3
Abnormal values for major measurable cardiovascular disease risk factors [59,138].

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Abnormal value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose</td>
<td>Impaired fasting glucose: between 6.1 and 7 mmol/l (110–125 mg/dL) Diabetes: ≥ 7.0 mmol/l (126 mg/dL)</td>
</tr>
<tr>
<td>Lipids</td>
<td>Total cholesterol Without diabetes: &gt; 5 mmol/l (190 mg/dL) With diabetes: &gt; 4.5 mmol/l (175 mg/dL)</td>
</tr>
<tr>
<td></td>
<td>LDL-cholesterol Without diabetes: &gt; 3 mmol/l (115 mg/dL) With diabetes: &gt; 2.5 mmol/l (100 mg/dL)</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Without diabetes: &gt; 140/90 mmHg With diabetes: &gt; 130/80 mmHg</td>
</tr>
</tbody>
</table>

Practical experience has shown that discouraging patients and healthcare staff from smoking on psychiatric wards and at clinics is a useful first step towards smoking cessation [56,120,132].

6.2. Body weight

Maintaining a healthy body weight and shape by healthy eating and regular physical activity is the key component of lowering CVD risk and prompt action is needed in patients who are overweight at initial assessment or who show signs of early weight gain with antipsychotic medication. Patients should be advised to lose weight if they have:

- BMI > 25 kg/m² (especially if it is greater than 30 kg/m²);
- waist circumference greater than 88 cm in women or greater than 102 cm in men.

A recent meta-analysis of 10 randomised trials involving 482 patients receiving antipsychotics was undertaken to assess the effectiveness of lifestyle modification. The trials, which lasted for 2–6 months and included studies that described the prevention of treatment emergent weight gain as well as the treatment of established obesity, found a statistically significant reduction in mean body weight of around 2.5 kg with lifestyle modification compared with usual treatment [3].

Referral to a nutritionist/dietician/personal trainer or lifestyle programme should be considered [53,54–56]. Lifestyle advice/support should include information about the importance of healthy eating and regular exercise [59]. Patients should be advised to take 30 minutes of moderately vigorous activity — at least a brisk walk — on most days of the week.

Lifestyle advice/support must include information about the importance of healthy eating and regular exercise [59]. Patients should be advised to take 30 minutes of moderately vigorous activity — at least a brisk walk — on most days of the week. Referral to a nutritionist/dietician/personal trainer or lifestyle programme could be considered.

Consideration should be given to switching antipsychotic when an individual gains significant amount of weight, particularly when the therapeutic response has been limited. Several pharmacological agents have been tried to reverse or prevent antipsychotic-induced weight gain. No drug has been found to be particularly effective but a recent systematic review showed that there was preliminary evidence that metformin may attenuate weight gain in both adult and adolescent patients taking atypical antipsychotics [95,140]. While larger trials of longer duration are needed, metformin may be considered in patients with additional risk factors, such as a personal or family history of metabolic dysfunction.

6.3. Diabetes and fasting blood glucose

The World Health Organisation (WHO) defined diabetes as a fasting plasma glucose of 7 mmol/L or more (126 mg/dL) [7,23,52,138]. In an asymptomatic individual, the diagnosis should be confirmed with a second fasting measurement on another day. The measurement of HbA1c may be used in the future for diagnosing diabetes [129].

In all forms of diabetes, inadequate control of glycaemia will result in complications of diabetes. These complications include diabetic neuropathy, diabetic retinopathy, diabetic kidney disease and an increased risk of infection. The goal of metabolic control should be to achieve HbA1c levels below 7% of total haemoglobin.

Patients with type 2 diabetes are likely to require additional pharmacological management, but this should be no different from the general population, for which guidelines are available from the EASD and the American Diabetes Association (ADA) [6].

Psychiatric centres should cooperate with diabetes centres to establish shared care of patients with mental illness and diabetes. For patients who require insulin treatment a diabetes nurse educator from a diabetes centre should be available upon request for patients in psychiatry units.

Patients with diagnosed diabetes should be seen by a physician and/or a diabetes nurse regularly and as required depending on the therapy used. Fasting blood glucose and HbA1c should be measured regularly (approximately every 3–6 months). An annual examination should include measurement of CVD risk factors, urinary albumin excretion and serum creatinine, an eye examination, ideally including fundus photography, and foot examination to diagnose early signs of complications [6].

Insulin treatment should be initiated and monitored by healthcare professionals with expertise in the management of diabetes. Special attention should be given to the prevention of hypoglycaemia in patients on insulin treatment. Avoidance of hypoglycaemia is best achieved by involving the patient’s family and carers in the education process about the risks and consequences of hypoglycaemia. Education of the patients on insulin should include blood glucose monitoring and the adaptation of the insulin doses based upon the values.

Patients with impaired fasting glucose, defined by the WHO as fasting glucose between 6.1 and 7 mmol/l (110–125 mg/dL), have high risk of diabetes and increased risk of CVD and so particular care is needed to ensure that these individuals undergo annual monitoring of glucose level and CVD risk.
In the presence of different CVD risk factors in people with SMI, closer monitoring should be considered. There have been several studies that have shown that lifestyle intervention is effective in the prevention of type 2 diabetes. These programmes have involved dietary modification, weight loss and increased physical activity. The principles of these programmes are similar to those used in the lifestyle modification programmes in people with SMI.
described above. Consequently, these programmes are expected to have benefits, in terms of diabetes prevention although this has not been formally tested in people with SMI.

The Diabetes Prevention Program also demonstrated that metformin is associated with a reduction in incident diabetes. For diabetes prevention, a Consensus Development Panel recommended metformin use only for very-high-risk individuals (those with combined impaired fasting glucose and impaired glucose tolerance, who are obese and under 60 years of age with at least one other risk factor for diabetes). In addition, the panel highlighted that in the Diabetes Prevention Program, metformin was most effective compared to lifestyle in those with BMI of at least 35 kg/m² and those under age 60 years [98].

There is preliminary evidence that metformin improves insulin sensitivity, glucose and HbA1c in people with SMI [95,140]. In the absence of long-term studies of combined antipsychotic and metformin therapy, consideration may be given to the use of metformin in high-risk patients.

6.4. Fasting blood lipids

Management of elevated fasting lipid levels should be carried out in the context of total CVD risk assessment (Fig. 1).

Target levels of total cholesterol and LDL-cholesterol are less than 5 mmol/l (190 mg/dL) and less than 3 mmol/l (115 mg/dL) respectively. More rigorous goals of less than 4.5 mmol/L (175 mg/dL) and less than 2.5 mmol/L (100 mg/dL) are recommended for patients with established CVD or diabetes (Table 3).

Patients should be encouraged to eat lean meat, fish and low fat dairy products and to replace saturated fat with monounsaturated and polyunsaturated fats from vegetable and marine sources [59]. Those with mildly elevated cholesterol levels may be able to reach target levels through diet alone, while others are likely to require lipid lowering therapy, usually with statins.

Statin treatment has been demonstrated to be effective in the management of dyslipidaemia in patients with SMI [44,62]. Psychiatrists who are involved in ongoing lipid management should be aware of the need for liver function and creatinine kinase tests.

If total CVD risk is high (Score ≥ 5% over 10 years for fatal CVD) then total cholesterol should be reduced to less than 5.0 mmol/l or less than 4.5 mmol/l in those with established CVD or diabetes.

6.5. Blood pressure

High blood pressure in severely mentally ill patients is often missed. Target blood pressure levels of less than 140/90 mmHg are recommended.

Lifestyle changes, such as stopping smoking, reducing salt intake, weight reduction and increased exercise, may be sufficient to reduce mildly elevated blood pressure, although some patients are likely to require pharmacological therapy. Recently updated European guidelines stress the importance of choosing antihypertensive agents best suited to individual patient’s needs [59,89].

6.6. Management of adverse drug-related effects on cardiovascular disease risk factors

Choice of psychotropic medication should take account of potential effects of different agents on CVD risk factors, such as weight and glucose levels and lipid profiles, especially in patients who are overweight or have diabetes or are at high total CVD risk factors. Clinical decision-making is always complex and has to consider efficacy aspects as well. A dilemma may arise with clozapine which is recommended by many guidelines as the antipsychotic of choice for those with refractory schizophrenia as clozapine is associated with the highest risk of weight gain and related CVD risk factors.

7. Summary and conclusion

The EPA, supported by the EASD and the ESC, published this statement with the aim of improving the care of patients suffering from SMI. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness amongst psychiatrists and primary care physicians caring for patients with SMI of the need to screen and treat increased cardiovascular risk factors and diabetes.

In addition, the academic associations involved with this statement point out that more research is required concerning the cardiovascular problems of people with SMI and their treatment.

8. Conflicts of Interest – Financial Disclosure Statement

This position statement was written without funding of pharmaceutical companies.

Prof. Prof. Dr. De Hert has been a consultant for, received grant/ research support and honoraria from and been on the speakers/ advisory boards of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck JA, Pfizer and Sanofi-Aventis. Prof Dekker has received grants and honoraria from Astra Zeneca, Bayer, Merck & Co Inc, Novartis, Novo Nordisk and Pfizer.

Dr. Dr. Kahl received honoraria from Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Bristol-Myers Squibb, Otsuka and Wyeth. Professor Wood has received unrestricted educational grants from, served on advisory boards of or/and given invited lectures for Astra Zeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Sanofi-Aventis, Schering Plough, Servier Laboratories and Sun Pharma, India. Prof. Holt has been a consultant for, has received funding to attend conferences and/or has served as a speaker or on advisory boards for Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novo Nordisk.

Prof. Dr. Möller has received grants or is a consultant for and on the speakership bureaus of Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck JA, Pfizer and Sanofi-Aventis.
Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Novartis, Organon, Pfizer, Sanofi-Aventis, Sepracor, Servier and Wyeth.

Acknowledgement

The authors would like to thank all members and staff of the EPA, the EASD and the ESC who contributed to the development of this position statement.

References


[38] Correll CU, Frederikson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10(7):661–70.


